The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Medscape2d
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
Young women see dramatic spike in cancer rates compared to young men. Why? It’s complicated
Young women are now nearly twice as likely to get cancer as young men in the U.S. - but there is no one reason why. New ...
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
Science Daily2d
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
The American Journal of Managed Care2d
FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.